Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth

INTRODUCTION: Recently, the pleiotropic benefits of incretin-based therapy have been reported. We have previously reported that Exendin–4, a glucagon-like peptide–1 (GLP–1) receptor agonist, attenuates prostate cancer growth. Metformin is known for its anti-cancer effect. Here, we examined the anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsutsumi, Yoko, Nomiyama, Takashi, Kawanami, Takako, Hamaguchi, Yuriko, Terawaki, Yuichi, Tanaka, Tomoko, Murase, Kunitaka, Motonaga, Ryoko, Tanabe, Makito, Yanase, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595004/
https://www.ncbi.nlm.nih.gov/pubmed/26439622
http://dx.doi.org/10.1371/journal.pone.0139709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595004/
https://www.ncbi.nlm.nih.gov/pubmed/26439622
http://dx.doi.org/10.1371/journal.pone.0139709

Ejemplares similares